A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 82
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : CEL
Long Form : chronic eosinophilic leukemia
No. Year Title Co-occurring Abbreviation
2019 A novel fusion gene involving PDGFRB and GCC2 in a chronic eosinophilic leukemia patient harboring t(2;5)(q37;q31). GCC2, PDGFRB
2019 JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. IL-3R, JAK2, MPNs, PV
2018 A multimodality work-up of patients with Hypereosinophilia. HE, HES
2018 A Very Rare Case of Hypereosinophilic Syndrome Secondary to Natural Killer/T-Cell Lymphoma. HES, NK/T
2018 Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRalpha kinase inhibitor for PDGFRalpha driving chronic eosinophilic leukemia. ---
2018 [Targeted sequencing analysis of hyper-eosinophilic syndrome and chronic eosinophilic leukemia]. HES
2017 Lyn mediates FIP1L1-PDGFRA signal pathway facilitating IL-5RA intracellular signal through FIP1L1-PDGFRA/JAK2/Lyn/Akt network complex in CEL. FIP1L1, IL-5RA, IR, MBP
2016 Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12. CML, ET, IRRs, IRs, MDS, MPNs, NHWs, PV, RS
2016 Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China. CHR, CMR, TKI
10  2016 Mediastinal Mass with Hyper-eosinophilia in a Young Boy -A Diagnostic Dilemma. SVCO
11  2015 F604S exchange in FIP1L1-PDGFRA enhances FIP1L1-PDGFRA protein stability via SHP-2 and SRC: a novel mode of kinase inhibitor resistance. F604S, HES
12  2014 Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRalpha-expressing cells. FIP1L1-PDGFRalpha, HES, TKI
13  2014 Murine models of eosinophilic leukemia: a model of FIP1L1-PDGFRalpha initiated chronic eosinophilic leukemia/systemic mastocytosis. HES, SM, WHO
14  2014 Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRalpha: roles of Mcl-1 and beta-catenin. TKIs, WT
15  2013 E- and p-selectins are essential for repopulation of chronic myelogenous and chronic eosinophilic leukemias in a scid mouse xenograft model. CML
16  2013 Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study. CHR, CMR, HES
17  2013 Oncostatin M is a FIP1L1/PDGFRA-dependent mediator of cytokine production in chronic eosinophilic leukemia. OSM, SDF-1
18  2012 Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL. FIP1L1, HES, HSC, IR, JAK, PC, siRNA, STAT
19  2012 Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model. ---
20  2012 [Characteristics of cytogenetics and molecular biology in patients with eosinophilia]. CEL, NOS, HES, RT-PCR, TCR
21  2011 Clinical features and outcomes of eosinophilic myocarditis patients treated with prednisolone at a single institution over a 27-year period. ---
22  2011 Molecular diagnosis and targeted therapy of a pediatric chronic eosinophilic leukemia patient carrying TPM3-PDGFRB fusion. ---
23  2011 Myeloprolipherative disorder type chronic myeloid leukemia--eosinophilic form. INF-alfa
24  2011 Successful treatment of ulcerative colitis associated with hypereosinophilic syndrome/chronic eosinophilic leukemia. HES, IM, PDGFRA, UC
25  2011 [Successful treatment with low-dose dasatinib in a patient with chronic eosinophilic leukemia intolerant to imatinib]. ---
26  2010 Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study. AEC, HES
27  2010 FIP1L1/PDGFR alpha-associated systemic mastocytosis. HES, SM
28  2010 Long-term exposure of leukemia cells to multi-targeted tyrosine kinase inhibitor induces activations of AKT, ERK and STAT5 signaling via epigenetic silencing of the PTEN gene. CML, PTEN
29  2010 Pure red cell aplasia associated with imatinib-treated FIP1L1-PDGFRA positive chronic eosinophilic leukemia. ---
30  2010 Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). AHNMD, SM
31  2010 [Clinical manifestations and treatment of chronic eosinophilic leukemia (CEL)/idiopathic hypereosinophilic syndrome (HES) in Japan]. HES
32  2009 A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. FIP1L1-PDGFRA, HES
33  2009 Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. CHR, HES
34  2009 FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia. HES, PCR-RFLP, RT-PCR
35  2009 FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. ---
36  2009 Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. HES, PDGFRalpha
37  2009 Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia. HES
38  2009 Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. TK
39  2008 A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. CHR, HES
40  2008 Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. TK
41  2008 Extramedullary molecular evidence of the 5'KIAA1509/3'PDGFRB fusion gene in chronic eosinophilic leukemia. ---
42  2008 FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib. HES, RT-PCR
43  2008 FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome. BM, BMMCs, HES, MC, SCF, SM
44  2008 Improvement of cardiac function, mitral regurgitation and pulmonary hypertension in a patient with chronic eosinophilic leukemia (CEL) after low dose imatinib therapy. ---
45  2008 The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers. CIMF, CML, CMPD, CMPD-U, ET, MRD, PV
46  2008 [Chronic eosinophilic leukemia with complex karyotypic abnormalities including trisomy 8]. ---
47  2008 [Clinicopathologic studies of 13 cases of chronic eosinophilic leukemia]. BMB
48  2008 [FIP1L1/PDGFRalpha fusion gene-negative chronic eosinophilic leukemia with t(5;12)(q31;p13): a case report and review of literatures]. ---
49  2008 [Studying of clinical and laboratory features of chronic eosinophilic leukemias /hypereosinophilic syndrome]. HES
50  2007 A case of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia with a rare FIP1L1 breakpoint. HES
51  2007 Chronic eosinophilic leukemia: a case report and review of literature. IHES
52  2007 Expressions of the VLA-4, LFA-1 and Mac-1 integrins in eosinophil migration in a case of chronic eosinophilic leukaemia. cGMP, Eo
53  2007 FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells. CFU-GM, CML
54  2007 FIP1L1-PDGFRA positive chronic eosinophilic leukemia in Tunisian patients. HES
55  2007 Hypereosinophilic syndrome, chronic eosinophilic leukemia, and mast cell disease. HES, IFN-alpha, MCD
56  2007 Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders. CML, CMML, ET, MPDs, PMF, PV, SMCD
57  2007 Interferon alpha induces a good molecular response in a patient with chronic eosinophilic leukemia (CEL) carrying the JAK2V617F point mutation. ---
58  2007 KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. ---
59  2007 Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. ---
60  2007 Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity. ---
61  2007 The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus. CML, SNP
62  2007 WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia. HES
63  2007 [Chronic eosinophilic leukemia with symptoms resembling Budd-Chiari syndrome due to liver infiltration]. BCS
64  2006 Chronic eosinophilic leukemia presenting with autoimmune hemolytic anemia and erythrophagocytosis by eosinophils. AIHA, NHL
65  2006 Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia. HES
66  2006 Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. FIP1L1-PDGFRalpha
67  2006 The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. FIP1L1, HES, IL-5
68  2005 The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases. FISH, HES, RT-PCR
69  2005 [The idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia]. ---
70  2004 Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. FISH, IHES, RQ-PCR
71  2004 Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib. PDGFRA
72  2004 Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. HES
73  2004 Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. HES
74  2004 The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. CML, FIP1L1, HES, PDGFRA
75  2003 Periodic oscillation of blood leukocytes, platelets, and hemoglobin in a patient with chronic eosinophilic leukemia. CFU-GM, CSFs, WBC
76  2003 [The T-lymphocyte clonal proliferation in a patient with chronic eosinophilic leukemia]. TCRbetaV
77  2002 The role of morphology, cytochemistry and immunohistochemistry in the diagnosis of chronic myeloproliferative diseases. CIMF, CMPD, CNL, ET, PV
78  2002 [Incidence and differential diagnosis of chronic eosinophilic leukemia]. ---
79  2001 Chronic eosinophilic leukemia with t(6;11)(q27;q23) translocation. PEIT, RT-PCR
80  1999 AlphaIFN-induced hematologic and cytogenetic remission in chronic eosinophilic leukemia with t(1;5). alpha-IFN
81  1999 The role of trisomy 8 in the pathogenesis of chronic eosinophilic leukemia. FISH
82  1997 Chronic eosinophilic leukaemia (CEL): a distinct myeloproliferative disease. ---